Genmab A/S (OTCMKTS:GNMSF – Get Free Report) hit a new 52-week low during trading on Wednesday . The stock traded as low as $184.08 and last traded at $184.08, with a volume of 11 shares trading hands. The stock had previously closed at $191.13.
Genmab A/S Stock Performance
The firm has a fifty day moving average price of $206.15 and a 200 day moving average price of $216.06. The company has a market cap of $12.30 billion, a price-to-earnings ratio of 10.63 and a beta of 1.08.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $5.70 earnings per share for the quarter, topping the consensus estimate of $0.46 by $5.24. Genmab A/S had a net margin of 36.30% and a return on equity of 19.75%.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
- Five stocks we like better than Genmab A/S
- What is a Special Dividend?
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- Stock Market Upgrades: What Are They?
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- Comparing and Trading High PE Ratio Stocks
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
